Michael Buckstein, MD of Mount Sinai explains the Phase II trial using combination of TACE and SBRT for unresectable single large HCC.
________
Preliminary results from this Phase II trial show very promising response rates when combining TACE+SBRT in large, unresectable HCC with excellent OS, PFS, and CSS. These preliminary data are currently being confirmed in an expanded cohort.
Advertisement